03.04.2013 - Clavis Pharma has become a target for a take-over after its cancer drug delivery technology failed proof-of-concept for the second time.
In November, US partner Clovis Oncology said it will terminate its partnership with the Norwegian drug developer after CP-4126 , a liposomal formulation of the chemotherapeutic gemcitabine, failed to prove superiority to the original drug in a Phase IIb study. Yesterday, the company’s second lead, elacytarabine, fell through in a pivotal Phase III study on 380 patients with refractory blood cancer AML.
Median survival in the elacytarabine arm was 3.5 months, compared to 3.3 months in the control arm. Adverse events were comparable between the two arms, and no meaningful differences were observed in any subgroup analyses. “We will review the strategic options for the company during the coming weeks, and shareholders will be informed about the alternatives available at a later date. Immediate steps will be taken to minimise our expenditure going forward, while caring for those patients who are still benefiting from elacytarabine,“ said CEO Olaf Hellboe.
All studies with the compound have been suspended. Hellboe announced that Clavis has a short-list of private Scandinavian firms that may be interested in a take-over of the public company. "We have taken two products all way through development with lipid technology and both failed in the big final test," said Helleboe. "That means it will be very difficult to justify putting huge investments in another product with the same technology.“
20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.
12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.
30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
Merck’s advanced water purification system with new high-throughput line delivers up to 9,000 liters of pure water daily with real-time monitoring and ensures constant water quality with low and predictable running costs. more